[Durgical](https://durgical.com/en/) › [DurgiPedia](https://durgical.com/en/durgipedia/) › [Embryology](https://durgical.com/en/embryology/) › [General embryology: weeks 1 to 8](https://durgical.com/en/embryology/areas/general/) › Stem cells: totipotent, pluripotent, embryonic and induced

# Stem cells: totipotent, pluripotent, embryonic and induced

- Topic

Stem cells can copy themselves and make other cell types. The earliest embryo cells can make everything; adult stem cells make only their own tissue.

Updated Nov 13, 2026

## Key points

- Totipotent: can form the embryo and the [placenta](https://durgical.com/en/histology/placenta/) (zygote, early blastomeres).
- Pluripotent: can form every cell of the body but not the trophoblast (inner cell mass, epiblast, ES and iPS cells).
- Multipotent: tissue-specific stem cells that form a limited family of cells, such as hematopoietic stem cells.
- ES cells come from the inner cell mass of a [blastocyst](https://durgical.com/en/physiology/fertilization-and-implantation/) (about day 5 after fertilization); human lines were first grown in 1998.
- iPS cells: adult cells reprogrammed with OCT4, SOX2, KLF4 and c-MYC (Yamanaka, 2006 mouse, 2007 human).
- Pluripotent cells left in a transplant can form teratomas, a key safety concern.

## What it is

A stem cell can both renew itself and give rise to more specialized cells. Potency shrinks as development proceeds: the zygote and early blastomeres are totipotent, cells of the inner cell mass are pluripotent, and tissue stem cells in the fetus and adult are multipotent. Embryonic stem (ES) cells are grown from the inner cell mass of a blastocyst; induced pluripotent stem (iPS) cells are adult cells reprogrammed to a similar state. Both are research tools, while blood stem cell transplantation is the established clinical use of stem cells.

## How to think about it

Potency is a budget that only shrinks: every fate decision closes doors. The zygote can still make the placenta; once the trophoblast splits off, inner cell mass cells can make any body cell but not placenta; tissue stem cells keep only their own family. iPS reprogramming is the one trick that reopens the doors, which is also why such cells can form tumours.

## Key facts

- Monozygotic twinning reflects early cell flexibility: an embryo split before the inner cell mass forms can give two complete individuals.
- Somatic cell nuclear transfer (cloning) showed that an adult nucleus can be reset by the oocyte cytoplasm.
- Pluripotency is kept by a network of [transcription factors](https://durgical.com/en/biochemistry/topics/transcription/) (OCT4, SOX2, NANOG) and by an open chromatin state.
- Hematopoietic stem cells for transplant come from bone marrow, mobilized peripheral blood or umbilical cord blood.
- Cord blood cells are immature, so [matching](https://durgical.com/en/epidemiology/matching/) is less strict, but blood counts recover more slowly.
- Teratomas and [sacrococcygeal teratomas](https://durgical.com/en/conditions/sacrococcygeal-teratoma/) show what uncontrolled pluripotent or germ cells can do: tissues of all three germ layers in one mass.

## Stem cells compared: potency, source and use

| Cell | Potency | Where it comes from | Can make placenta? | Main use or risk |
| --- | --- | --- | --- | --- |
| Zygote, early blastomere | Totipotent | Fertilized oocyte and its first divisions | Yes | Explains early monozygotic twinning |
| Embryonic stem (ES) cell | Pluripotent | Inner cell mass of the day 5 blastocyst | No | Research; ethical debate; teratoma risk |
| Induced pluripotent (iPS) cell | Pluripotent | Adult cell reprogrammed with OCT4, SOX2, KLF4, c-MYC | No | Disease models and drug testing; reprogramming and tumour risk |
| Hematopoietic stem cell | Multipotent | Bone marrow, mobilized blood, cord blood | No | Established transplant therapy |
| Spermatogonial stem cell | Unipotent | Testis | No | Makes sperm throughout adult life |

## Clinical notes

- Hematopoietic stem cell transplantation treats leukemias, lymphomas, myeloma, aplastic anemia, [sickle cell disease](https://durgical.com/en/conditions/sickle-cell-disease/) and thalassemia.
- Autologous transplants use the patient's own cells; allogeneic transplants use a matched donor, often a sibling.
- iPS cells from patients model diseases in the dish and in organoids and are used to test drugs.
- Ethical debate centres on the destruction of embryos for ES cell lines; iPS cells avoid this but carry their own risks (reprogramming errors, oncogenes).
- Many clinics sell unproven stem cell treatments; most proposed uses outside blood disorders remain experimental.

## Common traps

- **Pluripotent cells can form a whole embryo with its placenta**: they cannot make trophoblast; only totipotent cells can
- **iPS cells are simply ES cells without the ethical problem**: they avoid destroying embryos but carry reprogramming errors and oncogene risk
- **Stem cell therapy is proven for many diseases**: blood stem cell transplant is the established use; most other uses remain experimental
- **Cord blood behaves like bone marrow in every way**: matching can be less strict, but blood counts recover more slowly

## Test yourself

Think of the answer, then tap the question to see it.

## What distinguishes a totipotent cell from a pluripotent cell?

A totipotent cell can also form extraembryonic tissues such as the placenta; a pluripotent cell forms all body cells but not trophoblast.

## From which part of the embryo are embryonic stem cells derived?

From the inner cell mass of the blastocyst, around day 5 after fertilization.

## A boy with sickle cell disease receives bone marrow from his matched sister. Which cells do the work, and what is their potency?

Hematopoietic stem cells, which are multipotent: they renew themselves and make every blood cell type, but no other tissue.

## Which stem cell therapy is well established in clinical practice?

Hematopoietic stem cell transplantation, from bone marrow, peripheral blood or cord blood, for blood cancers and marrow disorders.

## A woman is offered stem cell injections for knee arthritis at a private clinic. What should she know about the evidence?

Outside blood and marrow disorders, most stem cell uses are still experimental; unproven treatments carry risks without proven benefit and are best checked against regulated clinical trials.

[Add to my cards (5)](https://durgical.app/estudiar/?add=/en/embryology/stem-cells-totipotent-pluripotent-embryonic-and-induced/)

## Connections

## Related 10

- [Week 1: cleavage, morula, blastocyst and implantation](https://durgical.com/en/embryology/week-1-cleavage-morula-blastocyst-and-implantation/)
- [Fertilization: capacitation, acrosome reaction and zona reaction](https://durgical.com/en/embryology/fertilization-capacitation-acrosome-reaction-and-zona-reaction/)
- [Week 3: gastrulation and the trilaminar disc](https://durgical.com/en/embryology/week-3-gastrulation-and-the-trilaminar-disc/)
- [Germ-layer derivatives: ectoderm, mesoderm, endoderm](https://durgical.com/en/embryology/germ-layer-derivatives-ectoderm-mesoderm-endoderm/)
- [Twins: dizygotic and monozygotic, chorionicity, twin–twin transfusion](https://durgical.com/en/embryology/twins-dizygotic-and-monozygotic-chorionicity-twin-twin-transfusion/)
- [Gene regulation and induction: how embryonic cells choose a fate](https://durgical.com/en/embryology/gene-regulation-and-induction-how-embryonic-cells-choose-a-fate/)
- [Assisted reproduction: IVF, ICSI and their risks](https://durgical.com/en/embryology/assisted-reproduction-ivf-icsi-and-their-risks/)
- [Fetal therapy: intrauterine transfusion, fetal medicines and surgery](https://durgical.com/en/embryology/fetal-therapy-intrauterine-transfusion-fetal-medicines-and-surgery/)
- [Blood, vessels and lymphatics: how they form in the embryo](https://durgical.com/en/embryology/blood-vessels-and-lymphatics-how-they-form-in-the-embryo/)
- [Umbilical cord: two arteries, one vein](https://durgical.com/en/embryology/umbilical-cord-two-arteries-one-vein/)

## Related conditions 2

- [Sickle cell disease](https://durgical.com/en/conditions/sickle-cell-disease/)
- [Thalassemias (α and β)](https://durgical.com/en/conditions/thalassemias/)

[← All of embryology](https://durgical.com/en/embryology/)

Educational content on embryonic development; not a guide to prenatal diagnosis or to medicines in pregnancy and no substitute for a health professional's advice. No doses are given.

Sources: [Types of Stem Cells — About Stem Cells](https://www.aboutstemcells.org/info/stem-cell-types) (International Society for Stem Cell Research, 2026); [Induced Pluripotent Stem Cells](https://www.aboutstemcells.org/info/induced-pluripotent-stem-cells) (International Society for Stem Cell Research, 2026); [Bone marrow transplant: MedlinePlus Medical Encyclopedia](https://medlineplus.gov/ency/article/003009.htm) (U.S. National Library of Medicine, 2026).

## **Spotted a mistake?** We are always improving for the community. Tell us what is wrong and our team will review it. Report a mistake

Representative model, for educational purposes only.

---
Source: https://durgical.com/en/embryology/stem-cells-totipotent-pluripotent-embryonic-and-induced/
License: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Cite as: DurgiPedia (durgical.com), https://durgical.com/en/embryology/stem-cells-totipotent-pluripotent-embryonic-and-induced/
